pembrolizumab: a promising agent for the treatment of mm
Published 7 years ago • 47 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
1:17
keynote-667: pembrolizumab plus copdac-28 for high-risk chl with slow early response to oepa
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
2:46
a phase ii trial of pembrolizumab for richter's transformation of cll
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
3:13
how to optimally sequence agents in the expanding treatment armamentarium of multiple myeloma
-
0:52
combining pembrolizumab with bcr inhibitors for richter's transformation
-
1:57
the safety and efficacy of iberdomide for the treatment of multiple myeloma
-
2:44
how is immunotherapy used to fight cancer? | dana-farber cancer institute | science illustrated
-
45:50
treating persistent/chronic itp current care, future potential
-
6:09
transforming therapy for patients with relapsed myeloma: the era of bispecific antibodies
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:15
results of dreamm-4: safety and efficacy of belantamab mafodotin with pembrolizumab in r/r myeloma
-
3:54
a case study from the ecog-e1910 trial: early blinatumomab treatment in all
-
2:09
heart transplantation in attr amyloidosis
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
5:07
daratumumab in the management of al amyloidosis
-
3:55
ziftomenib: a menin inhibitor for r/r npm1-mutated aml
-
4:20
therapy-related all: etiology, prognosis, and treatment
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:39
germline predisposition to clonal hematopoiesis and its role in leukemia progression
-
1:55
diagnosing and treating aml: the role of mutational profiling